Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

NCT00374660 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: Oxaliplatin
DRUG: Irofulven

Sponsor

Eisai Inc.